Teladoc: Minimal Growth Left As More Healthcare Players Leave/Diversify
Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure ...
Hims & Hers Stock Is Poised for a Major Surge in 2025
Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...
Hosted on MSN17h
Citigroup Downgrades Hims & Hers Health (HIMS)
Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...
Dow tumbles nearly 700 points Friday as strong jobs report casts doubt over Fed's rate-cut path
The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...
Finasteride for Hair Growth: Before and After Photos
When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.
AMD downgraded, Nike upgraded: Wall Street's top analyst calls
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...
What Is Pelvic Floor Dysfunction in Men? Causes, Symptoms, & Treatment
Pelvic floor dysfunction — or PFD — is a term for a variety of disorders that affect the muscles in your pelvic floor. If the ...
Hims & Hers Health down as Citi downgrades on GLP-1 revenue stream overvaluation
Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.